Description

4-(2′-Oxobenzimidazolin-1′-yl)piperidine (CAS No. 20662-53-7) is a high-purity heterocyclic organic compound with the molecular formula C₁₂H₁₅N₃O. This specialized chemical features a benzimidazol-2-one moiety linked to a piperidine ring, making it a valuable intermediate in pharmaceutical and biochemical research. With an IUPAC name of 3-piperidin-4-yl-1H-benzimidazol-2-one, it is supplied as a white to off-white crystalline powder with ≥95% purity (HPLC). Suitable for medicinal chemistry applications, this compound is meticulously packaged under inert conditions to ensure stability and longevity. Researchers can utilize this building block for the development of novel drug candidates, particularly in CNS-targeting therapies.

Properties

• CAS Number: 20662-53-7
• Complexity: 275
• IUPAC Name: 3-(4-piperidyl)-1H-benzimidazol-2-one
• InChI: InChI=1S/C12H15N3O/c16-12-14-10-3-1-2-4-11(10)15(12)9-5-7-13-8-6-9/h1-4,9,13H,5-8H2,(H,14,16)
• InChI Key: BYNBAMHAURJNTR-UHFFFAOYSA-N
• Exact Mass: 217.121512110
• Molecular Formula: C12H15N3O
• Molecular Weight: 217.27
• SMILES: C1CNCCC1N2C3=CC=CC=C3NC2=O
• Topological: 44.4
• Monoisotopic Mass: 217.121512110
• Synonyms: 4-(2′-Oxobenzimidazolin-1′-yl)piperidine, 1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one, 20662-53-7, 4-(2-Keto-1-benzimidazolinyl)piperidine, 1-(PIPERIDIN-4-YL)-1H-BENZO[D]IMIDAZOL-2(3H)-ONE, 3-piperidin-4-yl-1H-benzimidazol-2-one, MFCD00005714, 1-(piperidin-4-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one, 4RP0AED2PC, 1-(4-Piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one, 1-(piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one, 2H-Benzimidazol-2-one, 1,3-dihydro-1-(4-piperidinyl)-, DTXSID0057679, 4-(1-Benzimidazolinone)piperidine, 4-(2-oxo-1-benzimidazolinyl)piperidine, 4-(2-keto-1-benzimidazolinyl)-piperidine, 4-(2-Keto-1-benzimidozolinyl)piperidine, 1-(piperidin-4-yl)-1h-benzimidazol-2-ol, 1-(4-piperidyl)-3-hydrobenzimidazol-2-one, UNII-4RP0AED2PC, Benperidol Imp. A (EP); 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one; Benperidol Impurity A, EINECS 243-950-3, PIMOZIDE_met013, SCHEMBL42480, SCHEMBL44492, SCHEMBL220219, 4-(2-oxo-2,3-dihydro-benzimidazol-1-yl)-piperidine, SCHEMBL4211305, SCHEMBL9876669, 4-piperidyl-2-benzimidazolinone, CHEMBL3331429, DTXCID1031468, ALBB-034377, Tox21_113910, CCG-40889, SBB042778, STK519516, 1-(4-piperidyl)-2-benzimidazolinone, 1-(4-piperidyl)benzimidazolin-2-one, AKOS000268914, AKOS005177353, 1-(4-piperidinyl)-2-benzimidazolinone, 4-(2-keto-1-benzimidazolyl)piperidine, 1-(4-piperidinyl)-2-oxobenzimidazoline, 4(2-keto-1-benzimidazolinyl)piperidine, 4-(2-oxobenzimidazolin-1-yl)piperidine, 4-(2-keto-1-benzimidazolinyl)piperadine, NCGC00262912-01, 1-(4-Piperidyl)benzimidazol-2(3H)-one, 3-(4-Piperidyl)-1H-benzimidazol-2-one, 4-(2-Keto-1-benzoimidazolinyl)piperidine, 4-(2-oxo-1-benzimidazolinyl) piperidine, 4-(2-oxo-1-benzimidazolinyl)-piperidine, AC-13177, AS-35672, BP-12472, PIMOZIDE IMPURITY A [EP IMPURITY], SY081598, 1-(4-piperidinyl)-2H-benzimidazol-2-one, 4-(2-keto-1 – benzimidazolinyl)piperidine, CAS-20662-53-7, 1-(4-PIPERIDINYL)-2-BENZIMIDAZOLONE, 4-(2-OXO-1-BENZIMIDAZOLY)PIPERIDINE, CS-0200083, NS00026711, ST50308509, EN300-34383, 1-(Piperidin-4-yl)-1H-benzo[d]imidazol-2-ol, 4-(2-Keto-1-benzimidazolinyl)piperidine, 98%, 1-piperidin-4-yl-1,3-dihydrobenzimidazol-2-one, 1-piperidin-4-yl-1,3-dihydro-benzimidazol-2-one, AE-641/30111017, R-30507, 1,3-dihydro-1-(4-piperidinyl)benzoimidazol-2-one, 1-Piperidin-4-yl-1,3-dihydro-benzoimidazol-2-one, SR-01000630997-1, 1-piperidin-4-yl-1,3-dihydro-2H-benzimidazol-2-one, Q27260404, 1,3-Dihydro-1-(piperidin-4-yl)-2H-benzimidazol-2-one, 1-(4-piperidinyl)-1,3-dihydro-2(2H)-benzimidazolone, 4-(1,3-Dihydro-2H-benzimidazol-2-on-1-yl)piperidine, 4-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidine, 4-(2-OXO-1,3-DIHYDROBENZIMIDAZOL-1-YL)PIPERIDINE, 1,3-dihydro-1-(piperidin-4-yl)-2H-benzo[d]imidazol-2-one, 4-(2-OXO-1,3-DIHYDRO-2H-BENZIMIDAZOL-1-YL)PIPERIDINE

Application

This compound serves as a key synthetic intermediate in the development of pharmaceutical agents targeting neurological disorders. Researchers employ it in the synthesis of potential dopamine receptor modulators and serotonin antagonists. The benzimidazole-piperidine scaffold makes it particularly useful for CNS drug discovery programs. It has shown promise in early-stage research for Parkinson’s disease therapeutics.

Safety and Hazards

GHS Hazard Statements

• H301 (93.5%): Toxic if swallowed [Danger Acute toxicity, oral]
• H315 (93.5%): Causes skin irritation [Warning Skin corrosion/irritation]
• H319 (93.5%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
• H335 (93.5%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

Precautionary Statements

• P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501

Hazard Classes and Categories

• Acute Tox. 3 (93.5%)
• Skin Irrit. 2 (93.5%)
• Eye Irrit. 2 (93.5%)
• STOT SE 3 (93.5%)

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.